热门资讯> 正文
Teva提交ecopipam治疗儿童抽动秽语症的NDA
2026-06-19 05:20
- 梯瓦制药(TEVA) 0
- 高盛(GS) 0
- 美国银行(BAC) 0
- Teva Pharmaceutical Industries (TEVA) has submitted an NDA to the US FDA seeking approval of ecopipam for pediatric Tourette syndrome.
- The application is supported by phase 3 data that found ecopipam significantly delayed time to relapse compared to placebo during an open-label treatment period. For up to 24 weeks, Ecopipam led to and sustained a meaningful reduction in the severity of tics.
- Ecopipam is considered a first-in-class drug that works to inhibit dopamine signaling at the D1 receptor.
More on Teva Pharmaceutical
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Teva's Growth Story Is No Longer Just Generic, It's Getting Branded
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Alvotech gains on FDA acceptance of Entyvio biosimilar BLA
- Alvotech seeks U.S. nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again
推荐文章
华盛早报 | 存储集体暴跌！韩媒曝英伟达Rubin产量预期下调；谷歌将跻身道指成分股；美银力挺AI牛市至2028年
美股异动 | 科技股全线暴跌！闪迪跌超13%，美光跌超8%，迈威尔科技跌超5%
美股前瞻 | 科技股遭抛售潮！纳指期货盘前大跌2.5%；SpaceX连跌三天获“木头姐”狂买3200万美元；机构称美联储年内加息可能较低
新股申购 | 安克创新H股今起招股！一手入场费10032.16港元
华盛早报 | 股价三连跌市值蒸发超6000亿美元！SpaceX再重挫16%；港股“ETF之王”易主！南方两倍做多海力士年内累涨逾10倍
美股前瞻 | 万斯称美伊谈判取得积极进展！SpaceX首度发行无抵押债券，盘前一度大跌近6%；联电据报将与英特尔合作开发3nm芯片
“AI 教父”痛批马斯克旗下xAI堪称失败，警示AI将迎巨大泡沫破裂！
美联储如期按兵不动，但鹰派明显！预期年底前将加息25个基点
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
